Our Products
We are Bio Pharma
Leading the Way in Biosimilars, Our Expansive Portfolio Sets
Industry Standards
Adalix
- INN: Adalimumab
- Indications: Treatment of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
- Strengths: 40mg/0.4ml in Pre-filled Syringe (PFS)
- Mechanism of Action: TNF-α inhibitor that reduces inflammation by blocking tumor necrosis factor-alpha (TNF-α).
Glarise
- INN: Insulin Glargine
- Indications: Management of Type 1 and Type 2 diabetes mellitus to maintain long-term blood glucose control.
- Strengths: 100 IU/3ml in Pre-filled Pen (PFP)
- Mechanism of Action: Long-acting basal insulin providing a steady release to mimic natural insulin secretion.
Pneumotect
• INN: Pneumococcal Vaccine
• Indications: prevent infections caused by 13 different types of Streptococcus pneumoniae bacteria, which can lead to diseases like pneumonia, meningitis, and sepsis.
• Vaccine Type: Conjugated
• Mechanism of Action: Pneumotect works by inducing an immune response against the polysaccharides (sugars) found on the surface of the 13 targeted serotypes of Streptococcus pneumoniae.
Meningotect
• INN: Meningococcal Vaccine
• Indications: prevent meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135Vaccine
• Type: Conjugated
• Mechanism of Action: Meningotect works by exposing the immune system to a harmless form of the antigens (surface proteins) found on the bacterial cell surface of Neisseria meningitidis
Zostect
• INN: Zoster Vaccine
• Indications: prevent herpes zoster (shingles) in adults 50 years and older.
• Type: Recombinant
• Mechanism of Action: works by using a recombinant glycoprotein E, a protein found on the varicella-zoster virus (VZV), the virus that causes shingles.
Epolix
- INN: Erythropoietin Alpha
- Indications: Treatment of anemia associated with chronic kidney disease, chemotherapy, or HIV.
- Strengths: 2000 IU and 4000 IU in Pre-filled Syringe (PFS)
- Mechanism of Action: Stimulates red blood cell production by mimicking natural erythropoietin.
DulaGlyx
• INN: Dulaglutide
• Indications: Treatment of type 2 diabetes mellitus in adults as an adjunct to diet and exercise to improve glycemic control.
• Type: Recombinant
• Mechanism of Action: Dulaglutide is a GLP-1 receptor agonist that enhances insulin secretion and suppresses glucagon release, improving glycemic control in adults with type 2 diabetes.
Erenix
• INN: Erenumab
• Indications: Preventive treatment of migraine in adults • Type: Monoclonal antibody (mAb)
• Mechanism of Action: inhibits the action of CGRP, a neuropeptide involved in migraine pathophysiology, thereby reducing the frequency and severity of migraine episodes.
Melanix
• INN : Ipilimumab
• Indications : Treatment of advanced melanoma, a type of skin cancer
• Type: Monoclonal antibody (mAb)
• Mechanism of Action: By blocking CTLA-4, Ipilimumab effectively “releases the brake,” enhancing the body’s immune response against tumor cells.
UsteFlex
• INN: Ustekinumab
• Indications: treatment of moderate to severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy
• Type: Monoclonal antibody (mAb)
• Mechanism of Action: Inhibits the action of IL-12 and IL-23, which are key mediators in the inflammatory processes of psoriasis, psoriatic arthritis, and Crohn’s disease.
